The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants
Tokarski, J.S., Newitt, J., Chang, C.Y.J., Cheng, J.D., Wittekind, M., Kiefer, S.E., Kish, K., Lee, F.Y.F., Borzilerri, R., Lombardo, L.J., Xie, D., Zhang, Y., Klei, H.E.(2006) Cancer Res 66: 5790-5797
- PubMed: 16740718 
- DOI: 10.1158/0008-5472.CAN-05-4187
- Primary Citation of Related Structures:  
2GQG - PubMed Abstract: 
Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL. Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL. Although imatinib has a high rate of clinical success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL ...